Elite Pharmaceuticals Inc (ELTP):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C10080)
◆英語タイトル:Elite Pharmaceuticals Inc (ELTP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10080
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:44
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥79,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Elite Pharmaceuticals Inc (Elite) is a specialty pharmaceutical company focuses on the development of oral sustained and controlled release drug products. The company manufactures and develops generic drugs with Abbreviated New Drug Applications (ANDA) and branded drugs with New Drug Application (NDA) for the treatment of pain, obesity, hypertension, depression, infection and allergy, among others. Elite also has a pipeline of abuse-deterrent opioids for the treatment of chronic pain. The company uses its proprietary ART (abuse-deterrent technology) platform to develop and manufacture oral, controlled-release drugs. Elite is headquartered in Northvale, New Jersey, the US.

Elite Pharmaceuticals Inc (ELTP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Elite Pharma Acquires Trimipramine ANDA from Mikah Pharma 11
Elite Pharma Acquires Thirteen Abbreviated New Drug Application from Mikah Pharma 12
Partnerships 13
Elite Pharma Amends Co-Development and Licensing Agreement with SunGen Pharma 13
Elite Pharma Enters into Co-Development and Licensing Agreement with SunGen Pharma 14
Licensing Agreements 15
Elite Pharma Enters into Licensing Agreement with Glenmark Pharma 15
Glenmark Pharma Enters into Licensing Agreement with Elite Pharma 16
Elite Pharma Enters into Licensing Agreement with Epic Pharma for Abuse-Deterrent ELI-200 17
Elite Pharma Enters Into Licensing Agreement With Epic Pharma For Twelve Generic Products 18
Equity Offering 19
Elite Pharma to Raise USD40 Million in Private Placement of Shares 19
Elite Pharma to Raise Funds through Private Placement of Shares 20
Elite Pharma Announces Private Placement of Shares for USD40 Million 21
Elite Pharma Announces Private Placement Of Preferred Stock For US$5 Million 22
Elite Pharmaceuticals Inc – Key Competitors 23
Elite Pharmaceuticals Inc – Key Employees 24
Elite Pharmaceuticals Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Aug 09, 2018: Elite Pharmaceuticals reports financial results for the first quarter of fiscal year 2019 ended June 30, 2018 26
Jun 14, 2018: Elite Pharmaceuticals Announces Financial Results for the Fiscal Year Ended March 31, 2018 27
Feb 09, 2018: Elite Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2018 Ended December 31, 2017 28
Nov 09, 2017: Elite Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2018 Ended September 30, 2017 29
Aug 09, 2017: Elite Pharmaceuticals Reports Financial Results For The First Quarter Of Fiscal Year 2018 Ended June 30, 2017 30
Jun 14, 2017: Elite Pharmaceuticals, Reports Financial Results for the Fiscal Year Ended March 31, 2017 and Provides Conference Call Information 31
Feb 09, 2017: Elite Pharmaceuticals Reports Results For Third Quarter Of Fiscal Year 2017 32
Corporate Communications 33
Aug 07, 2018: Elite Pharmaceuticals appoints Aqeel A. Fatmi to its Board of Directors 33
Product News 34
Oct 24, 2018: Elite Pharmaceuticals reports positive results from a pivotal bioequivalence study 34
08/30/2017: Elite Pharmaceuticals to Present ELI-200 (SequestOx) Data at PAINWeek 2017 National Conference 35
07/07/2017: Elite Pharmaceuticals Reports Topline Results from a Pivotal Fed Bioequivalence Study for SequestOx 36
05/25/2017: Elite Pharmaceuticals SequestOx Study Results Expected In July 37
03/13/2017: Elite Pharmaceuticals Initiates Pivotal Bioequivalence Fed Study For Reformulated SequestOx 38
02/08/2018: Elite Pharmaceuticals and SunGen Pharma File ANDA 39
01/30/2018: Elite Pharmaceuticals Reports Positive Topline Results from SequestOx Pilot Study 40
Jan 17, 2017: Elite Pharmaceuticals Reports Positive Topline Results From A Pivotal Bioequivalence Study For A Generic OxyContin 41
Jan 10, 2018: Elite Pharmaceuticals Reports Positive Topline Results from Pivotal Bioequivalence Studies for an Extended-Release Generic 42
Product Approvals 43
Jan 23, 2017: Elite Reports On SequestOx FDA End-of-Review Meeting 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Elite Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Elite Pharma Acquires Trimipramine ANDA from Mikah Pharma 11
Elite Pharma Acquires Thirteen Abbreviated New Drug Application from Mikah Pharma 12
Elite Pharma Amends Co-Development and Licensing Agreement with SunGen Pharma 13
Elite Pharma Enters into Co-Development and Licensing Agreement with SunGen Pharma 14
Elite Pharma Enters into Licensing Agreement with Glenmark Pharma 15
Glenmark Pharma Enters into Licensing Agreement with Elite Pharma 16
Elite Pharma Enters into Licensing Agreement with Epic Pharma for Abuse-Deterrent ELI-200 17
Elite Pharma Enters Into Licensing Agreement With Epic Pharma For Twelve Generic Products 18
Elite Pharma to Raise USD40 Million in Private Placement of Shares 19
Elite Pharma to Raise Funds through Private Placement of Shares 20
Elite Pharma Announces Private Placement of Shares for USD40 Million 21
Elite Pharma Announces Private Placement Of Preferred Stock For US$5 Million 22
Elite Pharmaceuticals Inc, Key Competitors 23
Elite Pharmaceuticals Inc, Key Employees 24
Elite Pharmaceuticals Inc, Subsidiaries 25

List of Figures
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Elite Pharmaceuticals Inc (ELTP):製薬・医療:M&Aディール及び事業提携情報(Elite Pharmaceuticals Inc (ELTP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆